AUPHAurinia Pharmaceuticals Inc.Signing up patients
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 81 (planned)
- Started
- Apr 22, 2026
- Main results expected
- Mar 2, 2029
- Fully finished
- Mar 2, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events
Measured over: Baseline to study completion, up to 73 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07596901 · record last updated 2026-08-03 · checked 2026-11-09 15:47 UTC